Brokers have indicated continued optimism for share price growth with several ASX 200 stocks this week.
Let's check them out.
Resmed CDI (ASX: RMD)
The Resmed share price is $32.11, up 1% today and down 27% over 12 months.
Morgans renewed its buy rating on the ASX 200 healthcare share this week.
The broker trimmed its 12-month price target from $40.97 to $39.50.
This suggests a potential 23% upside ahead.
Resmed is among 8 ASX shares going ex-dividend next week.
Westpac Banking Corp Ltd (ASX: WBC)
The Westpac share price is $35.46, down 0.7% today and down 2% over 12 months.
UBS reaffirmed its buy rating on the ASX 200 bank share with a 12-month target of $45.
This suggests a potential 27% upside ahead.
Minerals 260 Ltd (ASX: MI6)
The Minerals 260 share price is 74 cents, down 4.9% today and up 471% over 12 months.
Nope, that's not a typo!
Minerals 260 is a gold mineral explorer building the Bullabulling Project in Western Australia.
In FY26, the miner was No. 2 among the 5 best-performing ASX 200 shares for capital growth.
UBS thinks this stock has more room to run.
The broker reiterated its buy rating on Minerals 260 shares with a price target of 90 cents.
This implies potential capital gains of 22% over FY27.
ANZ Group Holdings Ltd (ASX: ANZ)
The ANZ share price is $38.73, up 1.8% today and up 19% over 12 months.
ANZ reported an increase in its cash profit and net interest margin (NIM) for 3Q FY26 yesterday.
However, it noted a downturn in the value of mortgage loan applications since the Federal Budget.
Citi renewed its buy rating on ANZ shares with a $39.25 price target.
This suggests the ASX 200 bank stock is almost fully valued.
Sonic Healthcare Ltd (ASX: SHL)
The Sonic Healthcare share price is $22.19, down 1% today and down 22% over 12 months.
Healthcare is on a comeback tour after plunging to a nine-year low in June.
Since the sector turned on 3 June, ASX 200 healthcare shares have ripped 30% as a group.
Value investors have swooped in, and Sonic Healthcare is benefitting from the attention.
The Sonic Healthcare share price has risen 18% since 3 June.
This week, Bell Potter renewed its buy rating on Sonic Healthcare shares with a $28.75 target.
This implies potential capital growth of 30% over the next year.
Insurance Australia Group Ltd (ASX: IAG)
The IAG share price is $8.06, up 3.1% today and down 6% over 12 months.
UBS maintained its buy rating on IAG shares following the insurer's FY26 results yesterday.
The broker reduced its 12-month price target from $9.45 to $9.25.
This implies a potential 15% upside ahead for IAG shares.
Megaport Ltd (ASX: MP1)
The Megaport share price is $21.58, down 0.5% today and up 49% over 12 months.
UBS renewed its buy rating on the ASX 200 tech share on Wednesday.
The broker has a 12-month price target of $24.20 on Megaport shares.
This suggests a potential 12% upside ahead.
Bank of Queensland Ltd (ASX: BOQ)
The Bank of Queensland share price is $6.42, up 0.2% today and down 17% over 12 months.
Morgans reiterated its buy rating on the ASX 200 financial share with a price target of $6.94.
This implies a potential 8% upside ahead.
The post 8 ASX 200 shares with fresh buy ratings this week appeared first on The Motley Fool Australia.
Citigroup is an advertising partner of Motley Fool Money. Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Megaport and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended Sonic Healthcare. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2026